Leonard Schleifer (AP Images)
Regeneron adds more positive PhIII data for its NGF program — but safety is still a big concern
Two years after fasinumab hit its first late-stage bar, Regeneron is standing by its “high-risk, high reward” bet on the NGF antibody. But while …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
